PFE · 8-K · 20260804PR000094
Geographic Revenue Shift
PFIZER INC · 2026-08-04 · Importance 43 · Surprise 32 · From source text
Second-quarter U.S. revenue declined less than 1% to $8.857 billion, while international revenue increased 7% to $6.177 billion. Biopharma international revenue rose 7% to $5.871 billion, compared with essentially flat U.S. Biopharma revenue of $8.790 billion. International growth was particularly strong for Eliquis, up 14% to $773 million, Lorbrena, up 46% to $221 million, and Vyndaqel, up 12% to $698 million. Six-month international revenue increased 7% to $11.896 billion, versus 2% growth in the United States to $17.588 billion.
Key facts
- Total International revenues for Second-Quarter 2026: $6,177 million, up 7% (or 3% operational) versus 2025 source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +2.8% | Total International revenues for Second-Quarter 2026: $6,177 million, up 7% (or 3% operational) versus 2025 |